Reuters logo
BRIEF-Paratek projects pivotal phase 3 clinical study will report top-line data in Q2
December 13, 2016 / 12:13 PM / a year ago

BRIEF-Paratek projects pivotal phase 3 clinical study will report top-line data in Q2

Dec 13 (Reuters) - Paratek Pharmaceuticals Inc

* Paratek Pharmaceuticals Inc says projects its ongoing pivotal phase 3 clinical study will report top-line data during Q2 of 2017

* Paratek Pharmaceuticals - will be able to file new drug application for omadacycline for acute skin infections, pneumonia indications in H1 2018

* Press release - Paratek advances timing of top-line data for phase 3 community acquired bacterial pneumonia study to the second quarter of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below